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ABSTRACT 
 
Rational prescribing means prescribing the more effective and healthiest drug for a disease according to patient’s 
condition, the type of effective drugs, cost and etc. The non-normative and non-rational prescribing of medicine can 
cause side effects. Prescribing of effective and safe drugs can have an important role in treatment of patient and the 
lack of side effect, drug interactions and imposition of additional cost. The aim of this study was to evaluate drug 
interactions in prescriptions of Lorestan province, western of Iran In this study, at first, the statistic of the insurance 
prescription of all provincial pharmacies were obtained, interred in the prescription review software of food and 
drug administration, processed in terms of drug interactions and data were statistically analyzed. This study shows 
that of the total 1443973 of the prescription numbers, 1112 numbers of that contain 1.25 mg of Digoxin tablets with 
40 mg of Furosemide tablets that they have a severe interaction and can lead to arrhythmia in patients. Also 934 
prescriptions contain Gemfibrozil and Lovastatin which can lead to myopathy and rhabdomyolysis in consumer 
patients. The survey revealed that 1.36, 3.76 and 0.56% of prescriptions have mild, moderate and severe 
interactions, respectively. Existence of severe and moderate drug interactions requires that further workshops be 
held for physicians on drug interactions. 
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INTRODUCTION 
 
The specified responses of a drug, that is prescribed for a patient,can be changed by the other drug due to drug-drug 
interactions. Many of drug related problem (DRP)caused by drugs prescriptions and/or due to types of drug 
interactions [1, 2].Drug interaction have not only limited to cases of concurrent use of two or more drugs and can be 
seen as a several forms such as drug-drug interaction, drug-food, drug-environmental factors, cigarette smoking and 
laboratory tests and drug- patients [3].Every year, drug interaction causes several problems forpeoples and physicians 
don’t have enough time to monitor all patient for drug interactions harmful effects carefully. This phenomenon is 
mor important in those patients who use multi-drugs regimen and especially about those group who are taken up 
drugs without prescription[4, 5].Previous studies showed that drugs which have a low therapeutic index or their dose- 
response curves have a steeply slope, are more prone to the drug interaction. In these drugs, therapeutic dose is near 
to the toxic dose and a smallest change in the dose of drug causes changes in excretion, absorption and distribution 
of them and can leads to increase plasma concentration of drug. This causes toxic effects of the drug and 
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cardiovascular (CV) drugs with low therapeutic index are examples of these [6, 7].Therefore, the important part of 
screening for drug interaction is separating of clinical significant reactions from clinically insignificant reactions. 
 
In terms of the degree of severity, drug interaction can be divided into three categories include a) Severe interaction 
that clinically have great dangers for patient, such as sympathomimetic and inhibitors of monoamine oxidase 
inhibitor, b) Moderate interaction that have less clinical importance but there is still a risk for the patient such as 
Cimetidine and anticoagulant, and c) Mild interaction have a very little clinical importance and possible interactions 
can be eliminated by adjusting the time between drugs dose. Following factors may increase the interactions 
between drugs [8] [9]: 
 
a- Various pharmacological effects of a drug. 
b- People referral to several doctors in a short  
c- The use of prescribed drugs by the doctors and the drugs that the patients themselves usually use them. 
d- Improper use of drugs by the patient due to insufficient training. 
e- Concurrent prescription of two or more drugs with strong potency. 
f- Interaction with illegal drugs such as alcohol, morphine and other narcotics  
 
EXPERIMENTAL SECTION 
 
In this survey, at first, the statistic of the insurance prescription of all provincial pharmacies were obtained, interred 
in the prescription review software of food and drug administration, processed in terms of drug interactions and data 
were statistically analyzed by the processor prescription software. 
 
RESULTS 
 
This study shows that of the total 1443973 of the prescription numbers, 1112 numbers of that contain 25.mg of 
Digoxin tablets with 40 mg of Furosemide tablets that they have a severe interaction and can lead to arrhythmia in 
patients. Also 934 prescriptions contain Gemfibrozil and Lovastatin which can lead to myopathy and 
rhabdomyolysis in consumer patients. Percentage of interactions according to their severity were presented in Table 
1. 
 
Table 1.Percentage of interactions in Lorestan province doctors’ prescription in 2013 
 
Type of interactions Frequency 
Mild 1.36 
Moderate 3.76 
Severe 0.56 
 
DISCUSSION 
 
In the late 19th century, the first observations of drug interactions practically examined. One of the first reports is 
related to tubular excretion and increasing the plasma concentration of salicylates by Paraaminobenzoic acid 
(PABA). After that, many reports from desirable and undesirable results of use of drugs that were taking 
simultaneously, published in scientific journals Similar studies in Iran have been done in line with rational drug 
prescribing consuming and preventing drug interactions Rahidi and Senobar Tahaee conducted the study of the 
amount of drug interaction observed in the doctors insurance prescriptions in Kurdistan in 2000.Thier study 
demonstrated that of the total drug interactions observed, the rate of severe, intermediate and slight interactions were 
15.6%, 42.6% and 41.8% respectively[10].Also, evaluation of CV drugs interactions in insured prescriptions in Sari 
during the years2000–2001 showed that 40.2% of prescriptions contained CV drugs were prescribed by cardiology 
specialists, 18.4% were prescribed by other fields specialists and 41.4% were prescribed by general practitioners. 
Among the above prescription,50% of them had drug interaction that among the highest percentage of interactions 
observed in the prescriptions of other field specialist[11].In another similar study, the frequency distribution of drug 
interactions in the doctors insurance prescriptions of Gorgan city was examined. Of the total of 5300 prescription of 
53 doctors of Gorgan city in 1380, in 4367 cases (82%), drug interaction were observed that 38 cases (72.8%) were 
severe interactions, 302 cases (26.69%) were moderate interaction and the rest were mild interaction and percent of 
drug interaction in general practitioner was greater than specialist[12].In conducted studies by Nabavizadeh and 
Khoshnevisan in the general practitioners’ prescription of Yasuj city in 2003, among the 1100 drug prescription of 
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57 general practitioner, 169 cases of drug interactions reported that among them, 55.3% have severe interactions, 
55.54% have moderate interaction and 42% have mild interaction[13]. In addition, in a systematically review of the 
literature on the incidence and pattern of DDIs in Iran, it had been demonstrated that The most involved drug classes 
in DDIs were beta blockers, angiotensin-converting-enzyme inhibitors (ACEIs),diuretic agents, and non-steroidal 
anti-inflammatory drugs (NSAIDs)[14]. 
 
Despite of Iran, relatively few studies which were performed in the general population in developed countries also 
showed awide variability of estimates on incidence of drug-drug interaction (i.e.9.8% in Finland [15], 18.5% in 
Greece[16]. According to the above mentioned reports from Iran and other countries, there is wide range of difference 
between reported values for drug-drug interaction. Different study methods, various drug interaction databases, 
diverse study populations, different sample sizes, and some other factors have caused this considerable variability; 
therefore, direct comparison between the studies is impossible. 
 
In conclusion, the present study in Lorestan shows that drug interactions are somewhat inevitable and like other 
provinces, there is drug interaction in the doctors’ prescriptions. Existence of severe and moderate drug interactions 
requires that further workshops be held for physicians on drug interactions. Also, it is essential to revise the 
education system in the period of doctors’ education and continuous retraining with respect to the causes of the drug 
interactions should be done and practical training should be dealt with more importance and seriously.  
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